AS Number
AS25031
AS Name
NOVARTIS-CH
Org Name
Novartis AG
Country / Region
Switzerland
Registry

ripe

RegDate

Updated

2018-11-22T15:27:30Z

AS25031 Looking Glass
IPv4Prefixes

12

IPv6Prefixes

0

IPv4 NUMs

3,584

IPv6 NUMs(/64)

0

3,584 IPv4 Addresses
CIDR Description IP Num
160.61.168.0/23
ROA Signed and Valid IRR Valid
Novartis AG 512
160.61.170.0/23
ROA Signed and Valid IRR Valid
Novartis AG 512
160.61.208.0/24
ROA Signed and Valid IRR Valid
Novartis AG 256
160.61.211.0/24
ROA Signed and Valid IRR Valid
Novartis AG 256
160.62.0.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.1.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.2.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.3.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.4.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.5.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.6.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
160.62.7.0/24
ROA Signed and Valid IRR Valid
CH-NOVARTIS-20150306 256
AS Description Country / Region IPv4 NUMs IPv6 NUMs IPv4 IPv6
AS3303 SWISSCOM - Swisscom (Schweiz) AG, CH Switzerland 3,565,056 165,692,637,184 IPv4 IPv4
AS3356 LEVEL3 - Level 3 Parent, LLC, US United States 30,037,608 77,329,203,200 IPv4 IPv4
AS5400 BT - British Telecommunications PLC, GB United Kingdom 698,624 4,453,881,085,952 IPv4 IPv4
AS8220 COLT - COLT Technology Services Group Limited, GB United Kingdom 1,362,688 25,770,786,816 IPv4 IPv4
IP Address Domain NUMs Domains
160.61.171.254 1 chbs.cbi.cvpn.novartis.com
as-block:       AS24988 - AS25162
descr:          RIPE NCC ASN block
remarks:        These AS Numbers are assigned to network operators in the RIPE NCC service region.
mnt-by:         RIPE-NCC-HM-MNT
created:        2018-11-22T15:27:30Z
last-modified:  2018-11-22T15:27:30Z
source:         RIPE



aut-num:        AS25031
as-name:        NOVARTIS-CH
org:            ORG-NA7-RIPE
import:         from AS702 action pref=100; accept ANY
import:         from AS8220 action pref=100; accept ANY
import:         from AS6893 action pref=100; accept ANY
export:         to AS702 announce AS25031
export:         to AS8220 announce AS25031
export:         to AS6893 announce AS25031
default:        to AS702 action pref=100; networks ANY
admin-c:        NOVN1-RIPE
tech-c:         NOVN2-RIPE
abuse-c:        NAC45-RIPE
status:         ASSIGNED
mnt-by:         RIPE-NCC-END-MNT
mnt-by:         NOVARTIS-MNT
mnt-by:         COLT-CH-MNT
created:        2002-07-03T08:28:32Z
last-modified:  2018-11-21T11:58:12Z
source:         RIPE

organisation:   ORG-NA7-RIPE
org-name:       Novartis AG
country:        CH
org-type:       LIR
address:        Novartis Basel
address:        CH-4002
address:        Basel
address:        SWITZERLAND
phone:          +1 817 9167984
e-mail:         novartis.nic@novartis.com
admin-c:        NOVN1-RIPE
tech-c:         NOVN2-RIPE
abuse-c:        NAC45-RIPE
mnt-ref:        RIPE-NCC-HM-MNT
mnt-ref:        NOVARTIS-MNT
mnt-by:         RIPE-NCC-HM-MNT
mnt-by:         NOVARTIS-MNT
created:        2004-04-17T11:02:56Z
last-modified:  2020-12-16T12:53:17Z
source:         RIPE

role:           Novartis AG Administrative Contact
address:        CH-4002 Basel
address:        Switzerland
e-mail:         novartis.nic@novartis.com
remarks:        Role Account for general administrative issues
admin-c:        FK3907-RIPE
admin-c:        DM18522-RIPE
tech-c:         NOVN2-RIPE
nic-hdl:        NOVN1-RIPE
notify:         novartis.nic@novartis.com
mnt-by:         NOVARTIS-MNT
created:        2008-05-23T14:50:26Z
last-modified:  2021-09-15T20:59:27Z
source:         RIPE

role:           Novartis AG Technical Contact
address:        CH-4002 Basel
address:        Switzerland
e-mail:         novartis.nic@novartis.com
remarks:        Role Account for technical issues
admin-c:        NOVN1-RIPE
tech-c:         FK3907-RIPE
tech-c:         DM18522-RIPE
nic-hdl:        NOVN2-RIPE
notify:         novartis.nic@novartis.com
mnt-by:         NOVARTIS-MNT
created:        2008-05-23T14:50:26Z
last-modified:  2021-09-15T20:59:05Z
source:         RIPE